The contrasting signals, executive selling while a known external investor buys, suggest divergent views. Monitor for upcoming earnings or clinical trial updates that may have prompted Lindstrom’s confidence. Watch for follow-up trades from other board members or executives.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 20 $7.78entry
- T+1 · 9mo ago +8.10%α +9.11% · $8.41
- T+5 · 9mo ago +14.91%α +15.36% · $8.94
- T+20 · 8mo ago +5.14%α +11.09% · $8.18
- T+60 · 6mo ago +7.71%α +0.58% · $8.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider transactions at Ocular Therapeutix (OCUL) shows mixed activity: one significant open-market purchase by external investor Richard L. Lindstrom for $461K, alongside coordinated open-market sales by five executives totaling $256K. The selling executives include the Chief Development Officer, Chief Scientific Officer, Chief Strategy Officer, Chief Medical Officer, and Pravin Dugel (role unspecified), all selling near the same price point.
Key Financial Metrics
Key Facts
- Richard L. Lindstrom purchased 60,229 shares at $7.66 for $461,354.14 on February 20, 2026.
- Five insiders sold a combined 31,192 shares across February 20 and 23, 2026, for $256,374.36 in total.
- Selling insiders include four C-suite executives: Peter Kaiser (CDO), Jeffrey Heier (CSO), Sanjay Nayak (CSO), and Nadia Waheed (CMO), plus Pravin Dugel.
- All transactions were open-market trades; no derivative exercises or grants involved.
- Sales occurred at prices between $7.74 and $8.28 per share, near recent market levels.
Financial Impact
Net selling of $256K by insiders, offset by $461K purchase from external investor Lindstrom; net positive cash flow of $205K into stock.
Risk Factors
- Coordinated executive selling may signal lack of confidence in near-term prospects despite strong external buying.
- Lindstrom’s purchase, while large, is from a non-corporate insider and may reflect personal conviction rather than fundamental catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-OCUL-1772109078986 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers